Co-founded this consultancy to assist clients with a range of project scopes, including target discovery, target validation, and early drug development.

- Offer expert opinion on novel product development in cell therapy manufacturing. - Provide biology advice for quality control investigations in cell therapy manufacturing, supporting 40+ investigations.- Develop and deliver 15+ slide decks to communicate cell therapy manufacturing process to investigation team.

Evaluated human genetics supported target proposals for suitability as pipeline projects and prepared reports for leadership team

- Led and managed 3-member lab-based team for supporting target validation and drug discovery activities, including experimental strategy, budget, and project status communication.- Designed and managed research activities through CROs and academic collaborators for in vitro and in vivo studies, assay development, and other target validation activities. - Assessed human genetic and multiomic internal datasets to identify potential targets of interest, evaluated feasibility of pipeline projects, defended decisions with leadership team, and developed research strategies and budgets for projects.- Directed target validation and drug discovery programs in kidney disease, inflammatory disease (gout), and liver fibrosis, advancing liver disease small molecule program to lead optimization phase.

- Served as one of the founding members of R&D team, coordinating set up of laboratory space, and developing early strategy and process for target selection and prioritization.- Directed 2-member team to manage laboratory and provide experimental support for pipeline projects. - Developed target prioritization strategy and process for evaluation, prioritization, and selection of human genetics-backed drug discovery programs. - Led pipeline projects focused on kidney disease and inflammation. - Coordinated with ~10 CROs to manage target validation activities for projects.

- Managed and tracked internal genetic analysis research projects to ensure objectives were achieved and results were communicated. - Served as key point of contact and operational lead for genetic research project collaborations with academic groups and pharmaceutical consortiums, ensuring timely delivery of milestones and accurate reporting of findings. - Tracked and monitored in vivo and in vitro validation experiments for potential therapeutic targets identified from human genetic analysis.

- Led cross-site research program to engineer mammalian primary cells for therapeutic purposes.- Directed 6-member team in multiple gene editing and technology development projects. - Spearheaded technology development project focused on creating a novel strategy for inducible knock-out cell lines, resulting in publication in Cell Reports. (Guzzardo*, Rashkova* et al 2017)

Supervised 5-member team in generating CRISPR-Cas9 knock-in cell line products and evaluating new gene editing technologies for production.

- Drove technology development efforts and led 3-member team in generating CRISPR-Cas9 gene edited cell line products.- Generated 20+ CRISPR-Cas9 knock-in cell lines.

- Established pipeline for generation of CRISPR-Cas9 knock-in cell line products. - Contributed to project entailing development of novel gene tagging strategy, resulting in publication in Nature Communications. (Lackner et al 2015)

Measure and analyze the impact that scientists funded by the Damon Runyon Foundation have had in cancer research

I conducted my thesis research in Dr. Greg Hannon's laboratory where I studied genome surveillance pathways. Specifically, I studied small RNA and genome defense pathways in fruit fly, using high-throughput genome-wide RNAi screening and next generation sequencing (RNA-seq and ChIP-seq). Main project was published in Molecular Cell (Muerdter*, Guzzardo* et al 2013).

I worked in the lab of Dr. Carlos González studying the nonsense-mediated mRNA decay pathway in the budding yeast, Saccharomyces cerevisiae.